Imbruvica lassoes CLL indication

Share this article:

The FDA has expanded the indication for Johnson & Johnson and Pharmacyclics' Imbruvica to include chronic lymphocytic leukemia patients who have a chromosome 17 deletion which is associated with a poor response to standard CLL treatments.

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February. The FDA approved Imbruvica for the rare, aggressive cancer mantle cell lymphoma in November 2013.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.